PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects

About this update from Polypid Ltd.

[{"type":"text","content":"Locally Administered Docetaxel Through Extended-Release Delivery via the Company’s PLEX Technology Offers Potentially Enhanced Adjuvant Chemotherapy Option PETACH TIKVA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that animal studies related to OncoPLEX, the Company’s lead intra-tumoral product candidate in oncology applied as a paste to the resection bed during surgery, have been published in an abstract in the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Abstract Book. The abstract, reduction in local tumor recurrence in a murine R2 resection model comparing locally administered docetaxel-releasing product, OncoPLEX, versus systemic docetaxel, demonstrated that locally administered OncoPLEX potentially decreases the likelihood of tumor recurrence, with reduced side effects, compared to systemically administered chemotherapy agents. “We are pleased with the compelling results of these preclinical studies of OncoPLEX,” said Dr. Noam Emanuel, PolyPid’s Chief Scientific Officer and first author of the studies. “Despite advances in oncological surgery techniques and neoadjuvant and adjuvant treatments, local recurrence in many solid tumor malignancies still presents a challenge to the long-term survival of oncology patients. Addition of controlled local treatment to the current standard of care systemic chemotherapy could potentially lead to improved patient outcomes for certain devastating cancers, such as Glioblastoma Multiform (GBM). We look forward to advancing OncoPLEX into the clinic, with the objective of initiating a Phase 1/2 study.” OncoPLEX utilizes PolyPid’s novel PLEX technology to provide extended release, controlled local exposure to docetaxel, one of the most widely used chemotherapy agents, to potentially reduce local tumor recurrence and prolong patient survival. The studies consisted of two tests—one on CT26 (murine colorectal carcinoma—found to be resistant to docetaxel) and one on U-87 (human primary glioblastoma). In both animal model studies, OncoPLEX was applied once on the tumor bed post-tumor-resection. The control groups were treated with placebo or IV docetaxel in CT26 study and placebo or IP gemcitabine in U87 study every four days, for a total o...

More updates from Polypid Ltd.